Skip to main
LLY
LLY logo

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 41%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Eli Lilly reported a strong second quarter of 2025, surpassing expectations on both revenue and earnings while increasing its full-year guidance, indicating robust operational performance. Notably, sales for Mounjaro grew significantly, with a 60% increase quarter-over-quarter driven by new market entries in countries such as Brazil, Mexico, and India, suggesting strong demand for its cardiometabolic product line. Additionally, the introduction of orforglipron as an oral option in the GLP-1 market positions Eli Lilly favorably, enhancing its product offerings and market penetration in a growing therapeutic area.

Bears say

Eli Lilly faces significant downside risks impacting its financial outlook, particularly due to potential pricing and rebate pressures that could affect its market share. The trajectory of tirzepatide prescriptions has been worse than expected, and there are concerns regarding the drug's failure to demonstrate cardiac outcome benefits in specific patient populations, alongside a disappointing performance from Zepbound. Additionally, the competitive landscape is intensifying with orforglipron, which poses a global threat to Lilly's product offerings, further necessitating a reevaluation of peak sales forecasts amid heightened uncertainty.

Eli Lilly (LLY) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 41% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 17 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,064.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,064.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.